文献速递基础与转化研究新药、器械与细胞基因治疗研发

靶向诱导型免疫激活细胞因子递送重编程胶质母细胞瘤微环境并在小鼠模型中抑制肿瘤生长

Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models.
PubMed 文献 · Sci Transl Med · 2022-07-13

研究利用慢病毒载体平台在体外改造造血干细胞,使其单核/巨噬细胞后代在肿瘤部位时空选择性释放干扰素-α或白细胞介素-12。在同基因胶质母细胞瘤小鼠模型中,诱导型释放干扰素-α实现稳健肿瘤抑制直至根除,疗效、耐受性和特异性优于全身重组蛋白治疗;IL-12释放的时空控制对克服致死性造血毒性至关重要。

要点

  • 诱导型释放干扰素-α在肿瘤微环境内实现稳健肿瘤抑制直至根除。
  • 干扰素-α诱导释放的疗效、耐受性和特异性优于全身重组蛋白治疗。
  • IL-12释放的时空控制对克服致死性造血毒性并发挥抗肿瘤活性至关重要。

核心结论

  • 研究结果证明了一种针对胶质母细胞瘤的潜在治疗策略,并为近期启动的胶质母细胞瘤患者首次人体临床试验奠定基础。

研究设计与样本

  • 利用慢病毒载体平台在体外改造造血干细胞,使其肿瘤浸润单核/巨噬细胞后代在肿瘤部位时空选择性释放干扰素-α或白细胞介素-12。
  • 采用同基因胶质母细胞瘤小鼠模型进行体内研究。

主要发现

  • 肿瘤微环境内诱导型释放干扰素-α实现稳健肿瘤抑制直至根除,且在疗效、耐受性和特异性方面优于全身重组蛋白治疗。
  • 肿瘤免疫浸润单细胞RNA测序显示免疫微环境重编程为促炎和抗肿瘤状态,并与一个在人类胶质母细胞瘤中与不良预后相关的巨噬细胞亚群丢失相关。
  • IL-12释放的时空控制对克服致死性造血毒性至关重要,同时允许充分发挥其抗肿瘤活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma multiforme (GBM) is the most common and lethal brain tumor characterized by a strongly immunosuppressive tumor microenvironment (TME) that represents a barrier also for the development of effective immunotherapies. The possibility to revert this hostile TME by immunoactivating cytokines is hampered by the severe toxicity associated with their systemic administration. Here, we exploited a lentiviral vector-based platform to engineer hematopoietic stem cells ex vivo with the aim of releasing, via their tumor-infiltrating monocyte/macrophage progeny, interferon-α (IFN-α) or interleukin-12 (IL-12) at the tumor site with spatial and temporal selectivity. Taking advantage of a syngeneic GBM mouse model, we showed that inducible release of IFN-α within the TME achieved robust tumor inhibition up to eradication and outperformed systemic treatment with the recombinant protein in terms of efficacy, tolerability, and specificity. Single-cell RNA sequencing of the tumor immune infiltrate revealed reprogramming of the immune microenvironment toward a proinflammatory and antitumoral state associated with loss of a macrophage subpopulation shown to be associated with poor prognosis in human GBM. The spatial and temporal control of IL-12 release was critical to overcome an otherwise lethal hematopoietic toxicity while allowing to fully exploit its antitumor activity. Overall, our findings demonstrate a potential therapeutic approach for GBM and set the bases for a recently launched first-in-human clinical trial in patients with GBM.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Birocchi F, Cusimano M, Rossari F, et al. Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. Sci Transl Med. 2022. PMID: 35857642. doi:10.1126/scitranslmed.abl4106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。